European S3-Guidelines on the systemic treatment of psoriasis vulgaris
Guidelines for the treatment of psoriasis provide an overview of a variety of practical aspects relevant to selecting drugs and monitoring patients on therapy. Based on the evaluation of efficacy and safety data, as well as on the practical experience obtained with different treatment modalities, they contain a range of recommendations reached in a structured consensus process.
Epidemiological studies conducted in Germany and other countries, as well as the results of patient surveys in Europe and the United States, have indicated that mean disease activity in patients with psoriasis is high and quality of life is poor, even among patients who are seen regularly by dermatologists; moreover, these findings are accompanied by data showing low treatment satisfaction and a demand for more efficacious, safe, and practical therapies.